• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Endocrinology

Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis

byShayna BejaimalandAnees Daud
November 13, 2016
in Endocrinology, Gastroenterology
Reading Time: 3 mins read
Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis
Share on FacebookShare on Twitter

1. This prospective cohort study, conducted in Copenhagen, found that mild-to-moderate levels of non-fasting hypertriglyceridemia, from 177 mg/dL (2 mmol/L) and above, were associated with increased risk of acute pancreatitis.

2. These increases in risk for acute pancreatitis were greater than the corresponding risk of myocardial infarction within the same triglyceride range.

Evidence Rating Level: 2 (Good)

Study Rundown: It is well established that high levels (>885 mg/dL; >10 mmol/L) of plasma triglycerides is associated with acute pancreatitis, but it is unclear if this increased risk exists with mild-to-moderate elevation as well. This prospective cohort study aimed to determine if non-fasting mild-to-moderate hypertriglyceridemia (177-885 mg/dL; 2-10 mmol/L) was associated with acute pancreatitis.

Compared to individuals with triglyceride levels of <89 mg/dL (<1 mmol/L), there was a significant stepwise increase in risk of acute pancreatitis for every 89 mg/dL (1 mmol/L) increase in plasma triglyceride level. These increases in risk were greater than the risk of myocardial infarction with the same corresponding level of serum triglycerides. These results remained robust in multivariable regression when stratified for multiple potential confounders. Strengths of this study included its prospective design and using a population cohort. Limitations included inclusion of primarily Caucasian individuals of Danish descent. Additionally, there may have been misclassifications with the use of administrative diagnostic coding for cohort and outcome definitions.

Click to read the study, published in JAMA Internal Medicine

RELATED REPORTS

Reducing saturated fat decreases mortality in high-risk individuals

Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

Relevant Reading: Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study

In-Depth [prospective cohort study]: This prospective cohort study was conducted using data from the Copenhagen General Population Study (2003-2015) and the Copenhagen City Heart Study (1976-1978 data was collected, follow-up examinations occurred in 1981-1983, 1991-1994, 2001-2003). Median follow-up time was 6.7 years. The exposure of interest was plasma non-fasting triglycerides and these levels were obtained from the databases listed above. The outcome of interest was occurrence of acute pancreatitis as defined by ICD-8, ICD-10 codes for acute pancreatitis. Coding for myocardial infarction was also analyzed as a positive control. Statistical analysis included hazard ratios calculated with Cox proportional regression models. These models were adjusted for age, sex and risk factors for pancreatitis (education, smoking, hypertension, statin use, study cohort, birth year).

In all, 116,550 individuals from both databases with a triglyceride measurement were included in the study cohort. Compared to individuals with serum triglyceride levels of <89 mg/dL (1 mmol/L), the multivariable adjusted hazard ratios (HRs) for acute pancreatitis were as follows: 1.6 (95% CI 1.0-2.6) for levels of 89 – 176 mg/dL (1.00 to 1.99 mmol/L), 2.3 (95%CI 1.3-4.0) for 177 – 265 mg/dL (2.00 to 2.99 mmol/L), 2.9 (95%CI 1.4-5.9) for 266 – 353 mg/dL (3.00 to 3.99 mmol/L), 3.9 (95%CI 1.5-10.0) for 354 – 442 mg/dL (4.00 to 4.99 mmol/L), 8.7 (95%CI 3.7-20.0) for ≥443 mg/dL (≥ 5.00 mmol/L). The corresponding HRs for myocardial infarction were 1.6 (95%CI 1.4-1.9), 2.2 (95%CI 1.9-2.7), 3.2 (95%CI 2.6-4.1), 2.8 (95%CI 2.0-3.9) and 3.4 (95%CI 2.4-4.7), respectively. The results remained robust through all adjustment and stratification of potential confounders. There was also no statistical evidence of interaction.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cholesterolpancreatitis
Previous Post

Pembrolizumab associated improved survival for NSCLC compared to platinum-based chemotherapy

Next Post

Genotyping for HPV 16/18 may help guide colposcopy referrals for women with high risk HPV

RelatedReports

Dietary variety linked to greater increase in childhood BMI
Cardiology

Reducing saturated fat decreases mortality in high-risk individuals

December 15, 2025
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans

June 26, 2025
Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

June 10, 2025
CT texture analysis may predict liver insufficiency after hepatectomy
Pharma

Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis

April 15, 2025
Next Post
Decreased prevalence of HPV among vaccinated young females

Genotyping for HPV 16/18 may help guide colposcopy referrals for women with high risk HPV

Solitary kidney not associated with contrast-induced nephropathy

Ledipasvir-sofosbuvir may be safe treatment for kidney transplant recipients with chronic HCV

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Receipt of care from a patient-centered medical home is associated with better medication adherence

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.